Streamex Corp. (STEX) focuses on tokenizing real-world assets, with GLDY serving as its flagship gold-backed, yield-bearing token. At this early stage of building distribution, quarterly results receive more attention for signs of third-party adoption than for immediate profits. This third-quarter update is noteworthy because it shows whether GLDY momentum can continue scaling against a largely fixed cost structure. From what I see, the gap between growing gold reserves and an expanding net loss—largely from non-cash stock-based compensation—remains a key point of focus, along with the credibility of cash-burn reduction plans heading into year-end.
Streamex posted a third-quarter net loss of $17.5 million, or $(0.09) per share, compared with a net loss of $14.6 million, or $(0.08) per share, in the second quarter of 2026. The outcome exceeded the consensus estimate of a $(0.03) per share loss. Operating expenses reached $18.1 million, which included $9.3 million in non-cash stock-based compensation. Adjusted EBITDA came in at a $(7.2) million loss, versus $(6.6) million in the previous quarter.
Revenue included $145 thousand in GLDY lease income for the quarter and $291 thousand year-to-date, reflecting about 8% growth on a comparable basis after adjustments. No consolidated revenue figure was provided, so attention stayed on earnings per share and operational metrics. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Operationally, gold reserves supporting GLDY increased to 3,351 ounces from 3,111 ounces, adding 240 net new ounces against 15 in the prior quarter. The company issued 208 new GLDY tokens to subscribers, up from 27 previously, while external ownership of outstanding GLDY more than doubled to 17.7% from 9.0%. Assets under management for GLDY rose 12% to $14.0 million at market value.
Shares of STEX declined after the release, dropping roughly 5% in regular trading to around $0.31, close to its 52-week low. The initial move seemed tied to the earnings-per-share miss, especially given the modest consensus expectation that magnified the percentage impact. Sentiment stayed mixed, however, as investors weighed the wider loss against clear operational progress, including the doubling of external GLDY ownership, a new institutional allocation to a gold carry strategy, and advances in distribution partnerships. The price action indicates the market remains focused on the cash cost of scaling, even as the tokenized-gold product gains traction.
Looking ahead, the key question is whether Streamex can close the gap between product momentum and its cost base. Management targets reducing monthly operating cash burn to $1.1 million to $1.3 million from the current $1.5 million average within 90 days. Progress here will serve as an important indicator, given that fees grow with assets while costs remain largely fixed.
On the distribution side, several milestones stand out. CNB Custody became operational in October, providing qualified custody for registered investment advisers. Equity Trust Company is expected to launch GLDY on its IRA platform soon after the earnings call, positioning GLDY as the first tokenized asset available there and opening access to substantial retirement capital.
Investors should also track the rollout of Cask Foundation products, including liquidity bootstrapping for the Cask Gold Yield Vault (USGY) and the planned launch of GLDC, which could generate additional servicing revenue. Continued growth in gold backing GLDY and steady monthly yield distributions will help confirm durable third-party adoption. The balance between these catalysts and disciplined cash management should shape market views in coming quarters.
One tool I’ve found helpful for this kind of analysis is Tickeron’s AI Screener. It lets me filter stocks and ETFs by technical patterns, fundamentals, trends, and volatility to surface relevant opportunities more efficiently than manual methods. For tracking names like Streamex and the broader tokenized-asset space, it provides useful signals on momentum and related ideas.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The RSI Oscillator for STEX moved out of oversold territory on November 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 47 similar instances when the indicator left oversold territory. In 42 of the 47 cases the stock moved higher. This puts the odds of a move higher at 89%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for STEX just turned positive on October 26, 2026. Looking at past instances where STEX's MACD turned positive, the stock continued to rise in 40 of 46 cases over the following month. The odds of a continued upward trend are 87%.
Following a +12.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where STEX advanced for three days, in 217 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on STEX as a result. In 74 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STEX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for STEX entered a downward trend on November 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. STEX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.271) is normal, around the industry mean (3.120). P/E Ratio (-0.038) is within average values for comparable stocks, (6.734). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (0.809). Dividend Yield (0.000) settles around the average of (8.976) among similar stocks. STEX's P/S Ratio (526.316) is very high in comparison to the industry average of (16.899).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STEX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a development stage company which develops medical devices
Industry InvestmentBanksBrokers